



Q-REstrain
Cancer | Viruses | Lyme

Precision Gene Silencing Therapy

Innovative RNA interference therapy using your own cellular material to silence disease-specific gene sequences



From RGCC – Pioneers in Personalized Cancer Care Since 2004

myrgcc.com





What is Q-REstrain?

Q-REstrain is a breakthrough autologous therapy that harnesses your body's own genetic material to fight disease. We analyze your blood sample to identify and target disease-specific gene sequences using advanced RNA interference (RNAi) technology.

How It Works:

- 1. Target Detection** - We isolate and validate gene targets responsible for cancer, viruses, or Lyme pathogens
- 2. Precision Gene Silencing** - Patient-derived oligonucleotides are developed to block harmful gene expression at the RNA level
- 3. Therapeutic Action** - Therapy interrupts protein production and multiplication essential to disease survival while leaving healthy cells unharmed

The Q-REstrain Advantage:

- Personalized to each patient's unique genetic profile
- Targets disease at the molecular level

5-Step Process

Certified RGCC practitioners receive training and support through RGCC college and the RGCC practitioner network.

Step 1: Consultation

Patient connects with a trained RGCC practitioner who evaluates their case and determines if Q-REstrain is a good fit.

Step 2: Pre-Testing

Patient completes required diagnostic tests (Oncotrace for cancer or serum lab work for virus/Lyme).

Step 3: Blood Collection

Patient provides blood sample for personalized therapy development.


Step 4: Therapy Production

Customized Q-REstrain therapy is created in our state-of-the-art laboratory (14 working days).

Step 5: Treatment

Patient receives personalized therapy through an RGCC practitioner.

Proven Clinical Results





Who Can Benefit from Q-REstrain?

Cancer Patients

- Hematological cancers (blood cancers)
- Solid tumors (excluding CNS tumors)

Infectious Disease Patients:

- Lyme disease and co-infections (Borrelia, Bartonella, Babesia)
- Viral infections including Epstein-Barr virus (EBV), Human Herpesvirus (HHV), Cytomegalovirus (CMV)

Treatment Schedule

- **Cancer:** Maximum 4 treatments per year (3-month intervals)
- **Virus/Lyme:** Maximum 9 treatments per year (as frequent as 21-day intervals)

Important Considerations

- Not suitable for children under 5 (virus/Lyme) or 11 (cancer)
- Contraindicated during pregnancy or recent blood transfusions
- Certain concurrent treatments may affect eligibility
- Patients should consult with their RGCC Practitioner about other potential contraindications

Testimonial

“36-year-old female with Lyme and mold exposure. Couldn’t parent her small children without help, didn’t have the energy for exercise or family outings, spent her days in bed. Post burgdorferi Q-Restrain, dramatic increase in energy, was able to keep her kids while her husband was out of town without help for the first time. Planning activities for the family, adding back in exercise, energy is improved, pain decreased.”

Kristen Bailey Mills, MSN, APRN



Pre-Therapy Requirements

For Cancer Treatment:

- Oncotrace or other RGCC CTC test within 6 months
- Consultation with RGCC network practitioner

For Virus/Lyme Treatment:

- Positive serum lab results from reputable laboratory within 6 months
- No urine-based test results accepted

Why Choose Q-REstrain?

Unlike conventional therapies that affect both healthy and diseased cells, Q-REstrain offers:

- **Targeted precision**
- **Personalized approach**
- **Reduced side effects**
- **Scientific innovation**





About RGCC

Since 2004, RGCC has been blazing a trail in personalized cancer care through scientific discovery and innovation. Founded by genetics pioneer Dr. Ioannis Papasotiriou, we remain committed to developing patient-centric solutions that go beyond traditional treatment approaches.

Q-REstrain is available exclusively through the RGCC practitioner network.

Discover how our groundbreaking technologies are revolutionizing cancer screening, follow-up, and monitoring.

Visit myrgcc.com to learn more.

HEADQUARTERS

RGCC International GmbH

Baarerstrasse 95, 6300 Zug, Switzerland
+41 (0) 41 725 05 60
office@rgcc-international.com
rgcc-international.com

RGCC REGIONAL OFFICES

RGCC North America

Denver, USA
+1 (800) 813-1372
info@rgcc-international-northamerica.com

RGCC Southeast Asia

Singapore, Republic of Singapore
+65 8084 6380
info@rgcc-seasia.com

LABORATORY FACILITIES

RGCC International GmbH

Baar, Switzerland

Welmedis GmbH

Wädenswil, Switzerland

RGCC S.A.

Florina, Greece

RGCC Central Europe GmbH

Halle (Saale), Germany

RGCC India PVT LTD

Gajularamaram, Hyderabad, India

MEMBER OF



rgcc-international.com